...
首页> 外文期刊>Journal of Cancer >Demethylzeylasteral inhibits cell proliferation and enhances cell chemosensitivity to 5-fluorouracil in Colorectal Cancer cells
【24h】

Demethylzeylasteral inhibits cell proliferation and enhances cell chemosensitivity to 5-fluorouracil in Colorectal Cancer cells

机译:去甲基共甾运动抑制细胞增殖,并增强结直肠癌细胞中的5-氟尿嘧啶的细胞化学敏感性

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Malignant growth and chemotherapy resistance to 5-fluorouracil (5-FU) are the obstacles to the treatment of Colorectal cancer (CRC). There is need to develop effective therapeutic option. Demethylzeylasteral benefits to immune and anti-tumor function. However, the role demethylzeylasteral played in colorectal cancer remains unclear. Here, our study confirmed that demethylzeylasteral could inhibit the cell malignant capacity, such as proliferation, migration and invasion. And we also found demethylzeylasteral could cause cell cycle arrest and apoptosis. Followed we verified that combination demethylzeylasteral with 5-FU has a better curative effect in vitro. The two drugs function synergistically in SW480 and additionally in RKO. IC50 values of 5-FU decreased when combined with demethylzeylasteral. Next, we used the network pharmacology approach to explore the the potential molecular mechanism of demethylzeylasteral. We constructed the "Colorectal - targets - Demethylzeylasteral" and protein-protein interactions (PPI) networks. And 15 hub genes were found in PPI network. Then Gene Ontology (GO) enrichment analysis showed that demethylzeylasteral may affect cell cycle, apoptosis, invasion and response to chemotherapy drugs. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis indicated demethylzeylasteral may be involved in many cancer-related pathways. Taken together, the network pharmacology approach provided a potential mechanism of demethylzeylasteral in colorectal cells. Our study indicated that demethylzeylasteral could exert anti-tumor effects and enhance the sensitivity of the Colorectal cells to 5-FU, suggesting a promising ability to serve as an anti-cancer agent in Colorectal cancer.? The author(s).
机译:恶性生长和化疗耐药于5-氟尿嘧啶(5-FU)是治疗结直肠癌(CRC)的障碍。有必要开发有效的治疗选择。去甲基共甾体益处免疫和抗肿瘤功能。然而,在结肠直肠癌中起作用的作用脱甲基化术仍然尚不清楚。在这里,我们的研究证实,去甲基共甾体可以抑制细胞恶性能力,例如增殖,迁移和侵袭。我们还发现去甲基共甾体可能导致细胞周期停滞和细胞凋亡。我们验证了用5-fu的组合去甲基共甾体体体外更好的疗效。这两种药物在SW480中协同效果,另外在RKO中。与去甲基共甾运动结合时,5-FU的IC 50值下降。接下来,我们使用网络药理学方法来探讨去甲基共和剂的潜在分子机制。我们构建了“结肠直肠 - 靶标 - 去甲基共甾体”和蛋白质 - 蛋白质相互作用(PPI)网络。在PPI网络中发现了15个枢纽基因。然后基因本体论(GO)富集分析表明,去甲基共甾体可能会影响细胞周期,凋亡,侵袭和对化疗药物的反应。基因和基因组(Kegg)途径分析表明Demethylzeylasteral可能参与许多癌症相关途径的基因和基因组(Kegg)的京都植物。在一起,网络药理学方法提供了结直肠细胞中去甲基共甾体的潜在机制。我们的研究表明,去甲基共沸可以发挥抗肿瘤作用,提高结肠直肠细胞对5-FU的敏感性,表明有希望的能力作为结直肠癌中的抗癌剂。作者。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号